Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EIKN Eikon Therapeutics

Trading 09-14 10:10:42 EDT

9.12

+0.18

+2.01%

High9.18	Low8.93	Vol75.21K
Open8.95	D1 Closing8.94	Amplitude2.77%
Mkt Cap492.34M	Tradable Cap160.95M	Total Shares53.98M
T/O682.40K	T/O Rate0.43%	Tradable Shares17.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":9.12,"timestamp":1789395016227,"preClose":8.94,"halted":0,"volume":75212,"delay":0,"changeRate":0.020134228187919434,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Trading","change":0.18,"latestTime":"09-14 10:10:42 EDT","open":8.95,"high":9.1775,"low":8.93,"amount":682403.590416,"amplitude":0.027685,"askPrice":9.14,"askSize":110,"bidPrice":9.1,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":8.94,"latestTime":"09:06 EDT","volume":290,"amount":2608.9999350000003,"timestamp":1789391183135,"change":0.06,"changeRate":0.006711,"amplitude":0.001119},"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:30 EDT","volume":15,"amount":134.16,"timestamp":1789169408186,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.142376},"requestUrl":"/m/hq/s/EIKN/tweets","defaultTab":"tweets","newsList":[{"id":"2666730998","title":"Major Investor Makes Bold Move on Eikon Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666730998?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:06","pubTimestamp":1788919582,"startTime":"0","endTime":"0","summary":"New insider activity at Eikon Therapeutics, Inc. ( ($EIKN) ) has taken place on September 8, 2026. Significant shareholder Column Group GP IV LP ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637712","title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637712","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637712?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:34","pubTimestamp":1788899655,"startTime":"0","endTime":"0","summary":"Column Group IV GP reports purchase of 89,200 Eikon Therapeutics shares valued at $1.03 millionColumn Group IV GP reported a purchase of 89,200 Eikon Therapeutics common shares at USD 11.56.Indirect holdings reported at 4,312,139 shares via Column Group IV, 1,319,164 via Column Group Opportunity III, 148,840 via Column Group IV-A.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9sNLXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487978","title":"Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487978","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487978?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:32","pubTimestamp":1788435147,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics names Ching-Pin Chang as chief scientific officerEikon Therapeutics named Ching-Pin “CP” Chang executive vice president, chief scientific officer.Chang joins from Bristol Myers Squi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9l9Cns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU0267386448.USD","LU1585245621.USD","IE00BQXX3D17.EUR","IBB","MEDI","LU1934455194.USD","NDAQ","GILD","IE00BQXX3C00.GBP","LU1718418525.SGD","FTXH","LU2133065610.SGD","LU1023059063.AUD","BK4550","LU1236620834.HKD","LU2087621335.USD","LU2360032135.SGD","LU1093756325.SGD","BMY","LU2242652126.USD","BCDF","IHE","IE00BKPKM429.USD","LU2095319765.USD","TBXU","LU0306807586.USD","LU1983299246.USD","LU0109394709.USD","LU0965509010.AUD","LU2242646821.SGD","LU2125154778.USD","BMED","LU0114720955.EUR","BK4585","EIKN","IE00BN0W2V16.EUR","LU1291159041.SGD","LU0122379950.USD","IE00B64PRP62.GBP","LU1057294990.SGD","LU2089984988.USD","BIB","IBBQ","LU0321505868.SGD","LU0859254822.USD","LU1839511570.USD","SG9999014021.USD","TMED","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887923","title":"Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887923","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA3N4SRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781879","title":"Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781879","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664781879?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435000,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715602","title":"Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715602","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715602?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:31","pubTimestamp":1787743864,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics joins Cantor Global Healthcare Conference fireside chatEikon Therapeutics will join the 12th Annual Cantor Global Healthcare Conference in New York on Sept. 10, 2026 at 2:10 p.m. ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLVTLCl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","NDAQ","LU1720051017.SGD","LU1791710400.SGD","LU1244550221.USD","LU2089283258.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0267386448.USD","LU0557290698.USD","LU0912757837.SGD","LU0390134368.USD","BK4112","IE00BZ1G4Q59.USD","IAI","LU0210528500.USD","BCDF","KBWB","LU2095319765.USD","LU2028103732.USD","BK4516","LU0795875169.SGD","SG9999014005.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","LU1363072403.SGD","LU1074936037.SGD","LU1732799900.SGD","LU2271345857.HKD","BK4588","BK4581","SG9999014039.USD","BK4534","LU2487616109.SGD","LU0795875086.SGD","IE00B3QW5Z07.USD","LU1720051108.HKD","LU0158827948.USD","LU0882574139.USD","LU0971096721.USD","EIKN","IE00BGHQF748.EUR","LU0098860793.USD","BK4139","LU1244550494.USD","BK4127","IE00BKVL7J92.USD","LU2133065610.SGD","LU0320765646.SGD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662157667","title":"Eikon Therapeutics to Participate in Investor Conferences in September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662157667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662157667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:30","pubTimestamp":1787743800,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug.  26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351236/0/en/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449477","title":"Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449477?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084118,"startTime":"0","endTime":"0","summary":"Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncologyEikon Therapeutics will join a Cantor Fitzgerald-hosted KOL event on Aug. 20, 2026 at 9:00 a.m. ET.Chairman and C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLQxCq8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","NDAQ","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","EIKN","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4585","BCDF","SG9999014039.USD","IE00BQXX3F31.USD","BK4112","IE00BQXX3D17.EUR","SG9999014005.SGD","LU0314104364.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660929014","title":"Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2660929014","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660929014?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084100,"startTime":"0","endTime":"0","summary":"Event and Webcast to be held August 20th, 2026, 9:00 AM ETMILLBRAE, Calif., Aug.  18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3347241/0/en/eikon-therapeutics-to-participate-in-kol-event-on-therapeutic-use-of-parp-inhibitors-in-oncology-hosted-by-cantor-fitzgerald.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","KOL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480036","title":"Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480036?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:58","pubTimestamp":1786971506,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Eikon Therapeutics, Inc., with a price target of $32.00. Laa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144099","title":"Eikon Therapeutics Price Target Cut to $4.00/Share from $5.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144099?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:29","pubTimestamp":1786714140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659433021","title":"Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659433021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659433021?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:35","pubTimestamp":1786703738,"startTime":"0","endTime":"0","summary":"An update from Eikon Therapeutics, Inc. ( ($EIKN) ) is now available. On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q3-2026-oncology-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","EIKN","LU2065732104.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167560","title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167560","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167560?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652519,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/EIKN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659628611","title":"Eikon Net Loss Narrows 16% to $88.4 Million in Q2 FY26; R&D Expenses Rise 9% to $75.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659628611","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659628611?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651485,"startTime":"0","endTime":"0","summary":"Eikon net loss narrows 16% to $88.4 million in Q2 FY26; R&D expenses rise 9% to $75.5 millionEikon reported Q2 2026 net loss attributable to common stockholders narrowed to USD 88.4 million from USD 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3wk4Rj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","BK4139","BK4588","NDAQ","SG9999014039.USD","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","EIKN","BCDF","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516286","title":"Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344893/0/en/eikon-therapeutics-reports-second-quarter-2026-financial-results-and-provides-clinical-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LU2487616109.SGD","BK4189","BK4585","CNS","L","BK4139","DMC","BK4588","LU0210528500.USD","EIKN","BK4107","IND","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658846997","title":"Eikon Selects 0.6 Mg/m2 Dose for Eik1001 in TeLuRide-006 Advanced Melanoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658846997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658846997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447894,"startTime":"0","endTime":"0","summary":"Eikon selects 0.6 mg/m2 dose for EIK1001 in TeLuRide-006 advanced melanoma trialEikon Therapeutics selected a 0.60 mg/m2 dose for EIK1001 in the ongoing TeLuRide-006 adaptive Phase 2/3 trial in advanc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2gfygh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK4588","EIKN","IE00BGHQF748.EUR","SG9999014021.USD","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4112","IE00BN0W2V16.EUR","BK4585","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","BCDF","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992063","title":"Eikon Therapeutics - DMC Recommends Teluride-006 Study Continue as Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992063?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992060","title":"Eikon Therapeutics Announces Dose Selection for Teluride-006, an Ongoing Adaptive Phase 2/3 Trial of Eik1001 in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992060?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAB5KLWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658336339","title":"Eikon Therapeutics Appoints Johnny Bennett, Ph.d. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658336339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658336339?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUAQBMQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933604","title":"Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933604?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eikontx.com","stockEarnings":[{"period":"1week","weight":-0.1768},{"period":"1month","weight":-0.142},{"period":"3month","weight":0.0217},{"period":"6month","weight":-0.2199},{"period":"1year","weight":-0.5033},{"period":"ytd","weight":-0.5033}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eikon Therapeutics, Inc. was incorporated in Delaware on July 9, 2019. It is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, primarily in oncology. The leadership team has a notable track record of successfully developing impactful drugs. The company's strategy leverages a proprietary technology platform to create novel therapies, with lead candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.","exchange":"NASDAQ","name":"Eikon Therapeutics","nameEN":"Eikon Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eikon Therapeutics(EIKN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eikon Therapeutics,EIKN,Eikon Therapeutics股票,Eikon Therapeutics股票老虎,Eikon Therapeutics股票老虎国际,Eikon Therapeutics行情,Eikon Therapeutics股票行情,Eikon Therapeutics股价,Eikon Therapeutics股市,Eikon Therapeutics股票价格,Eikon Therapeutics股票交易,Eikon Therapeutics股票购买,Eikon Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eikon Therapeutics(EIKN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}